OneMedNet Stock Price, News & Analysis

OneMedNet (Nasdaq:ONMD) has announced a strategic partnership with Medcase to enter the $1.5 billion healthcare data annotation market. The collaboration leverages Medcase's network of 15,000+ healthcare professionals for medical data annotation services, while utilizing OneMedNet's iRWD™ platform and provider network for regulatory-grade, de-identified Real-World Data.

The partnership comes at a strategic time as the market is projected to reach $2.8 billion by 2030. The recent disruption caused by Scale AI's $14.8B investment from Meta has created opportunities for specialized healthcare providers. This collaboration positions OneMedNet to deliver recurring revenue streams by serving healthcare AI developers, pharmaceutical companies, and medical technology leaders.

OneMedNet (Nasdaq:ONMD) has expanded its partnership with one of the world's top five medical device companies through multiple revenue-generating projects under an evergreen master services agreement. The collaboration includes four distinct purchase orders focused on delivering regulatory-grade multimodal Real-World Data (RWD) to accelerate medical imaging AI model development.

The company leverages its iRWD™ network spanning over 1,750 provider sites to deliver comprehensive datasets that include advanced medical imaging data and complete patient histories. OneMedNet has already begun fulfilling these recent orders, demonstrating its efficient execution capabilities in providing curated, de-identified, and fit-for-purpose datasets for AI development, clinical trial enhancement, and healthcare outcome improvement.

OneMedNet (Nasdaq:ONMD) has significantly expanded its Cardiovascular Real-World Data (RWD) network by adding 85 cardiovascular centers and data sources, contributing approximately 2.7 million annual cardiovascular studies. This expansion positions OneMedNet as one of the largest providers of cardiovascular RWD.

The enhanced network provides de-identified cardiovascular imaging, diagnostic reports, and electrocardiograms (ECG) to life sciences companies, AI developers, and medical device manufacturers. This data is particularly valuable given that cardiovascular diseases (CVDs) cause 19.8 million deaths globally and generate $320 billion in annual costs in the US alone.

OneMedNet (NASDAQ:ONMD) has established a strategic partnership with Circle Cardiovascular Imaging (Circle CVI) to implement a new subscription revenue model. Circle CVI will utilize OneMedNet's iRWD™ platform to access de-identified cardiovascular imaging data from over 1,750 provider sites, encompassing 131 million exams.

The partnership enables Circle CVI to leverage OneMedNet's extensive real-world data network for AI model development, cardiac diagnostics, and treatment planning. Data delivery is expected within 30 days, marking a shift from one-time transactions to a continuous subscription-based collaboration focused on advancing cardiovascular healthcare innovation.

OneMedNet (NASDAQ:ONMD), an AI-powered Real-World Data company, reported significant financial improvements in Q2 2025. The company achieved an 80% reduction in total liabilities, decreasing from $19.7M to $6.2M, with an additional $1.9M reduction in July 2025.

Key financial highlights include $3.0M net income in Q2 2025, $3.7M raised through private placements, and holdings of 15 BTC valued at $1.6M. Operationally, OneMedNet expanded its provider network to 1,750 sites with access to 136M clinical studies, while enhancing its iRWD™ platform with improved AI capabilities and adding over 5 billion administrative records and claims.

OneMedNet (NASDAQ:ONMD), a leader in AI-powered Real-World Data (RWD), has announced a 25% expansion of its iRWD™ network and platform. The company now encompasses 1,750+ healthcare system partner sites, providing access to 34 million patients, 136 million clinical exams, and 5 billion administrative records.

The expansion significantly enhances OneMedNet's capability to provide insights into rare diseases, underserved populations, and health economics. Operating in the $60 billion RWE industry, the company is positioned for accelerated revenue growth through increased data licensing and new enterprise partnerships.

OneMedNet (NASDAQ:ONMD) has selected Inka Health, a subsidiary of Onco-Innovations, to spearhead an AI-driven oncology data analytics project focused on developing external control arms (ECAs) for clinical trials. The initiative aims to leverage OneMedNet's iRWD Real-World Data platform to create more efficient alternatives to traditional clinical trials.

The project will utilize Inka Health's SynoGraph platform, combining machine learning with causal inference methods, to validate an ECA for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer. This collaboration targets the Real-World Evidence (RWE) market, projected to reach $4.6 billion by 2030, and aims to accelerate cancer therapy development while reducing costs.

Onco-Innovations Limited (OTCQB:ONNVF) announced that its subsidiary Inka Health has been selected by OneMedNet (Nasdaq:ONMD) to lead an AI-driven oncology data analytics initiative. The project aims to develop external control arms (ECAs) using OneMedNet's regulatory-grade patient data to accelerate cancer therapy development.

The collaboration will utilize Inka Health's SynoGraph platform to validate an ECA for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer. This initiative targets the Real-World Evidence (RWE) market, projected to reach $4.6 billion by 2030. The project aims to demonstrate how real-world data can replicate traditional clinical trial results more efficiently, potentially reducing development costs and timelines.

The companies plan to submit their findings to ISPOR Europe 2025, positioning themselves at the forefront of AI-driven oncology research and drug development.

OneMedNet (NASDAQ:ONMD), a leader in AI-powered Real-World Data (RWD), shared significant achievements in a shareholder letter from CEO Aaron Green. The company has expanded its iRWD™ platform to include five major data marketplaces and grown its network to over 121 million clinical exams across 1,400 healthcare providers.

Key developments include implementing a new subscription-based Data License Agreement model to drive Annual Recurring Revenue, expanding AI-powered de-identification capabilities beyond healthcare into finance, telecom, and retail sectors, and achieving a threefold increase in qualified leads to over 130. The company's datasets meet FDA and international standards, positioning OneMedNet to capture a share of the projected $60-110 billion annual value in pharmaceutical and medical-device sectors through generative AI and RWD.